Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 50, 2010, Pages 21671-21676

  Järvinen, Tero A H ^a,b,c   Ruoslahti, Erkki ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Angiogenesis proteoglycan; CAR peptide; Cell penetrating peptide

Indexed keywords

ANTIFIBROTIC AGENT; CAR DECORIN FUSION PROTEIN; DECORIN; HYBRID PROTEIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; TISSUE REGENERATION; WOUND HEALING;

AMINO ACID SEQUENCE; ANIMALS; BLOOD VESSELS; CHO CELLS; CICATRIX; CRICETINAE; CRICETULUS; DECORIN; FIBROSIS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

MUS;

EID: 78650718332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016233107     Document Type: Article

References (55)

1. Aarabi S, Longaker MT, Gurtner GC (2007) Hypertrophic scar formation following burns and trauma: New approaches to treatment. PLoS Med 4:e234.
2. Shaw TJ, Martin P (2009) Wound repair at a glance. J Cell Sci 122:3209-3213.
3. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453:314-321.
4. Border WA, Ruoslahti E (1992) Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 90:1-7.
5. Brunner G, Blakytny R (2004) Extracellular regulation of TGF-β activity in wound repair: Growth factor latency as a sensor mechanism for injury. Thromb Haemost 92:253-261. (Pubitemid 39172305)
6. Ruoslahti E, Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities. Cell 64:867-869.
7. Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346:281-284.
8. Border WA, et al. (1992) Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360:361-364.
9. Li Y, et al. (2004) Transforming growth factor-β1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am J Pathol 164:1007-1019.
10. Weis SM, et al. (2005) A role for decorin in the remodeling of myocardial infarction. Matrix Biol 24:313-324.
11. Faust SM, Lu G, Wood SC, Bishop DK (2009) TGFβ neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection. J Immunol 183: 7307-7313.
12. Yan W, et al. (2009) Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-β/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 20: 1190-1200.
13. Reed CC, Iozzo RV (2002) The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19:249-255.
14. Järveläinen H, et al. (2006) A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 14:443-452.
15. Davies JE, Tang X, Denning JW, Archibald SJ, Davies SJ (2004) Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries. Eur J Neurosci 19:1226-1242.
16. Grisanti S, et al. (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: A pilot study. Invest Ophthalmol Vis Sci 46:191-196.
17. Li Y, et al. (2007) Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Mol Ther 15:1616-1622.
18. Zhu J, et al. (2007) Relationships between transforming growth factor-β1, myostatin, and decorin: Implications for skeletal muscle fibrosis. J Biol Chem 282:25852-25863.
19. Järvinen TAH, Ruoslahti E (2007) Molecular changes in the vasculature of injured tissues. Am J Pathol 171:702-711.
20. Ferguson MW, et al. (2009) Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 373: 1264-1274.
21. Bandyopadhyay B, et al. (2006) A "traffic control" role for TGFβ3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol 172:1093-1105.
22. Hildebrand A, et al. (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem J 302:527-534.
23. Yamaguchi Y, Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336:244-246.
24. Sullivan MM, et al. (2006) Matricellular hevin regulates decorin production and collagen assembly. J Biol Chem 281:27621-27632.
25. Seidler DG, et al. (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281:26408-26418.
26. Goldoni S, et al. (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173:844-855.
27. Fiedler LR, et al. (2008) Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of α2β1 integrin activity. J Biol Chem 283:17406-17415.
28. Ashcroft GS, et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1:260-266.
29. Lucas T, et al. (2010) Differential roles of macrophages in diverse phases of skin repair. J Immunol 184:3964-3977.
30. Goren I, et al. (2009) A transgenic mouse model of inducible macrophage depletion: Effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am J Pathol 175:132-147.
31. Mirza R, DiPietro LA, Koh TJ (2009) Selective and specific macrophage ablation is detrimental to wound healing in mice. Am J Pathol 175:2454-2462.
32. Grotendorst GR, Rahmanie H, Duncan MR (2004) Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 18: 469-479.
33. Grotendorst GR, Duncan MR (2005) Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 19: 729-738.
34. Leask A, Abraham DJ (2006) All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803-4810.
35. Midwood K, et al. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15: 774-780.
36. Desmoulière A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7-12.
37. Friedlander M, et al. (1996) Involvement of integrins α v β 3 and α v β 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 93:9764-9769.
38. St Croix B, et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202.
39. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90.
40. Christian S, et al. (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163:871-878.
41. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759-768.
42. Wang J, Dodd C, Shankowsky HA, Scott PG, Tredget EE, Wound Healing Research Group (2008) Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest 88:1278-1290.
43. Lyon M, Rushton G, Gallagher JT (1997) The interaction of the transforming growth factor-βs with heparin/heparan sulfate is isoform-specific. J Biol Chem 272: 18000-18006.
44. Rider CC (2006) Heparin/heparan sulphate binding in the TGF-β cytokine superfamily. Biochem Soc Trans 34:458-460.
45. Iwao K, et al. (2009) Heparan sulfate deficiency leads to Peters anomaly in mice by disturbing neural crest TGF-β2 signaling. J Clin Invest 119:1997-2008.
46. Chen Q, et al. (2007) Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-β (TGF-β) by modulating assembly of latent TGF-β-binding protein-1. J Biol Chem 282:26418-26430.
47. Kantola AK, Keski-Oja J, Koli K (2008) Fibronectin and heparin binding domains of latent TGF-β binding protein (LTBP)-4 mediate matrix targeting and cell adhesion. Exp Cell Res 314:2488-2500.
48. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274:4489-4492.
49. Carrino DA, et al. (2003) Age-related changes in the proteoglycans of human skin. Specific cleavage of decorin to yield a major catabolic fragment in adult skin. J Biol Chem 278:17566-17572.
50. Carrino DA, et al. (2010) Age-related differences in human skin proteoglycans. Glygobiol, 10.1093/glycob/cwq162.
51. Sayani K, et al. (2000) Delayed appearance of decorin in healing burn scars. Histopathology 36:262-272.
52. Baghy K, et al. (2010) Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest .
53. Urakami T, et al. (2010) Peptide-directed highly selective targeting of pulmonary arterial hypertension. Am J Pathol, in press.
54. Goldoni S, Iozzo RV (2008) Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123:2473-2479.
55. Iozzo RV, Schaefer L (2010) Proteoglycans in health and disease: Novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277: 3864-3875.